All In Biotech

Drug Trial Radar · NCT07410494

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

A Phase 1/2, Open-Label, Biomarker-Driven Study of Allogeneic Donor-Derived CAR-NK Cells With Antigen Selection by Tissue Biopsy and/or Liquid Biopsy Profiling in Participants With Relapsed/Refractory Advanced Solid Tumors (Single-Target vs Dual-Target Strategy)

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Dec 28, 2027

Study completion Dec 28, 2028

Sponsor

Lead sponsor
Essen BiotechAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 8 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.

Conditions

  • Cancer
  • Breast Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (Locally Advanced or Metastatic)
  • Prostate Cancer - Recurrent
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Ovarian Cancer
  • Glioblastoma
  • Melanoma (Skin Cancer)
  • Acute Myeloid Leukemia (AML)
  • Non Hodgkin Lymphoma
  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
  • Liver Cancer

Interventions

  • EB-SELECT Single-Target CAR-NK CellsBiological

    Donor-derived CAR-NK cells expressing a single CAR selected from the target menu. WITH Fludarabine (IV) + Cyclophosphamide (IV), administered prior to CAR-NK infusion. Similar conditioning drugs are used in CAR-NK solid tumor trials.

  • Dual-Target Antigen-Selected CAR-NKBiological

    Participants whose profiling identifies two actionable antigens, or strong evidence of antigen heterogeneity. WITH Fludarabine (IV) + Cyclophosphamide (IV), administered prior to CAR-NK infusion . Similar conditioning drugs are used in CAR-NK solid tumor trials.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, type, and severity of adverse events (AEs), graded by CTCAE v5.0Time frame: 28 DAYS
  2. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: 28 DAYS

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • District One Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.